Speaker Profile

Ph.D., CEO, Novosanis

Biography
Vanessa Vankerckhoven is CEO and co-founder of Novosanis, a University of Antwerp spin-off company specialized in medical devices. She is a passionate entrepreneur and in charge of the day to day management of Novosanis next to the strategic marketing of the oncology business within the Molecular Solutions Business Unit for Orasure Technologies. She holds a PhD in Medical Sciences and has a profound interest in infectious diseases, medical devices, diagnostics, microbiology, and vaccinology. She has a good track record of scientific publications as author and co-author in international peer-reviewed journals and has written several book chapters. Previously, she was appointed Research & Innovation Manager of the Vaccine and Infectious Disease Institute (VAXINFECTIO) at the University of Antwerp, Belgium, where she was responsible for setting-up and maintaining collaborations with industry and exploring opportunities for valorisation, including patents and spin-off creation.


Clinical Dx Showcase:
Novosanis

Novosanis is a wholly owned subsidiary of OraSure Technologies Inc (NASDAQ: OSUR) and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology.

Urine as a Non-invasive Liquid Biopsy for Oncology Applications
Urine is an exciting sample type that contains relevant biomarkers and has shown potential as a non-invasive liquid biopsy for detection and monitoring of urological, gynecological and systemic cancers. Urine sampling is also beneficial as it is easy, quick and non-invasive.

 Session Abstract – PMWC 2022 Silicon Valley


The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative